Argyria attributed to silvadene application in a patient with dystrophic epidermolysis bullosa.
Argyria is most commonly reported in association with prolonged ingestion of silver-containing medicaments. This case illustrates the rather unique case of development of argyria following application of silver sulfadiazine in a patient with epidermolysis bullosa.
Browning
John C
JC
Department of Dermatology, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA. johnbrowningmd@yahoo.com
Levy
Moise L
ML
D000279:Administration, Cutaneous; D000328:Adult; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000009:adverse effects*; D001129:Argyria / Q000097:blood / Q000209:etiology* / Q000473:pathology; D016108:Epidermolysis Bullosa Dystrophica / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D012834:Silver / Q000097:blood*; D012837:Silver Sulfadiazine / Q000008:administration & dosage / Q000009:adverse effects*; D012867:Skin / Q000473:pathology; D012869:Skin Absorption
D000891:Anti-Infective Agents, Local; D012834:Silver; D012837:Silver Sulfadiazine